{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,9]],"date-time":"2026-11-09T16:44:42Z","timestamp":1794242682204,"version":"4.9.0"},"reference-count":40,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,3,7]],"date-time":"2023-03-07T00:00:00Z","timestamp":1678147200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004281","name":"National Science Centre Poland","doi-asserted-by":"publisher","award":["2021\/41\/N\/NZ7\/02530"],"award-info":[{"award-number":["2021\/41\/N\/NZ7\/02530"]}],"id":[{"id":"10.13039\/501100004281","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004569","name":"Polish Ministry of Science and Higher Education","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004569","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100014416","name":"Narodowy Instytut Lek\u00f3w","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100014416","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomedicine &amp; Pharmacotherapy"],"published-print":{"date-parts":[[2023,5]]},"DOI":"10.1016\/j.biopha.2023.114490","type":"journal-article","created":{"date-parts":[[2023,3,15]],"date-time":"2023-03-15T07:35:46Z","timestamp":1678865746000},"page":"114490","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":47,"special_numbering":"C","title":["Anticancer effect and safety of doxorubicin and nutraceutical sulforaphane liposomal formulation in triple-negative breast cancer (TNBC) animal model"],"prefix":"10.1016","volume":"161","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4006-2682","authenticated-orcid":false,"given":"Anna","family":"Pogorzelska","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9197-5553","authenticated-orcid":false,"given":"Maciej","family":"Mazur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"\u015awitalska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4980-6606","authenticated-orcid":false,"given":"Joanna","family":"Wietrzyk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dawid","family":"Sigorski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7302-9520","authenticated-orcid":false,"given":"Krzysztof","family":"Fronczyk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2731-9535","authenticated-orcid":false,"given":"Katarzyna","family":"Wiktorska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.biopha.2023.114490_bib1","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.biopha.2018.06.066","article-title":"Clinical and molecular aspects of breast cancer: targets and therapies","volume":"106","author":"Godone","year":"2018","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.biopha.2023.114490_bib2","doi-asserted-by":"crossref","first-page":"6095","DOI":"10.1111\/febs.15583","article-title":"New insights into the activities and toxicities of the old anticancer drug doxorubicin","volume":"288","author":"van der Zanden","year":"2021","journal-title":"FEBS J."},{"key":"10.1016\/j.biopha.2023.114490_bib3","doi-asserted-by":"crossref","first-page":"853","DOI":"10.4103\/0973-1482.139267","article-title":"An overview of doxorubicin formulations in cancer therapy","volume":"10","author":"Rivankar","year":"2014","journal-title":"J. Cancer Res. Ther."},{"key":"10.1016\/j.biopha.2023.114490_bib4","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1007\/s10741-020-09977-1","article-title":"Anthracycline-induced cardiotoxicity and renin-angiotensin-aldosterone system\u2014from molecular mechanisms to therapeutic applications","volume":"27","author":"Sobczuk","year":"2022","journal-title":"Heart Fail. Rev."},{"key":"10.1016\/j.biopha.2023.114490_bib5","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1177\/0960327119888277","article-title":"A review on the cardioprotective mechanisms of metformin against doxorubicin","volume":"39","author":"Ajzashokouhi","year":"2020","journal-title":"Hum. Exp. Toxicol."},{"key":"10.1016\/j.biopha.2023.114490_bib6","first-page":"460","article-title":"Effect of anthracycline antibiotics on oxygen radical formation in rat heart","volume":"43","author":"Doroshow","year":"1983","journal-title":"Cancer Res."},{"key":"10.1016\/j.biopha.2023.114490_bib7","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2021.111708","article-title":"Doxorubicin-induced cardiotoxicity: an update on the molecular mechanism and novel therapeutic strategies for effective management","volume":"139","author":"Rawat","year":"2021","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.biopha.2023.114490_bib8","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1371\/journal.pone.0193918","article-title":"Sulforaphane potentiates anticancer effects of doxorubicin and attenuates its cardiotoxicity in a breast cancer model","volume":"13","author":"Bose","year":"2018","journal-title":"PLoS One"},{"key":"10.1016\/j.biopha.2023.114490_bib9","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2019.109635","article-title":"Targets and mechanisms of sulforaphane derivatives obtained from cruciferous plants with special focus on breast cancer \u2013 contradictory effects and future perspectives","volume":"121","author":"Jabbarzadeh Kaboli","year":"2020","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.biopha.2023.114490_bib10","first-page":"1","article-title":"Natural compounds against doxorubicin-induced cardiotoxicity: a review on the involvement of Nrf2\/ARE signaling pathway","author":"Yarmohammadi","year":"2020","journal-title":"Phyther. Res."},{"key":"10.1016\/j.biopha.2023.114490_bib11","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13045-021-01199-8","article-title":"A lysosome-targeted dextran-doxorubicin nanodrug overcomes doxorubicin-induced chemoresistance of myeloid leukemia","volume":"14","author":"Zeng","year":"2021","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.biopha.2023.114490_bib12","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/j.ijpharm.2019.01.008","article-title":"In the triple-negative breast cancer MDA-MB-231 cell line, sulforaphane enhances the intracellular accumulation and anticancer action of doxorubicin encapsulated in liposomes","volume":"558","author":"Mielczarek","year":"2019","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.biopha.2023.114490_bib13","doi-asserted-by":"crossref","first-page":"5501","DOI":"10.7150\/thno.27721","article-title":"Self-assembly of porphyrin-grafted lipid into nanoparticles encapsulating doxorubicin for synergistic chemo-photodynamic therapy and fluorescence imaging","volume":"8","author":"Hameed","year":"2018","journal-title":"Theranostics"},{"key":"10.1016\/j.biopha.2023.114490_bib14","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/0022-1759(83)90303-4","article-title":"Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays","volume":"65","author":"Mosmann","year":"1983","journal-title":"J. Immunol. Methods"},{"key":"10.1016\/j.biopha.2023.114490_bib15","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1371\/journal.pone.0155772","article-title":"The comparison of MTT and CVS assays for the assessment of anticancer agent interactions","volume":"11","author":"\u015aliwka","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.biopha.2023.114490_bib16","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1177\/1947601912440575","article-title":"Quantitative methods for assessing drug synergism","volume":"2","author":"Tallarida","year":"2011","journal-title":"Genes Cancer"},{"key":"10.1016\/j.biopha.2023.114490_bib17","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1186\/s12885-019-5939-z","article-title":"Mechanisms of doxorubicin-induced drug resistance and drug resistant tumour growth in a murine breast tumour model","volume":"19","author":"Christowitz","year":"2019","journal-title":"BMC Cancer"},{"issue":"25","key":"10.1016\/j.biopha.2023.114490_bib18","doi-asserted-by":"crossref","first-page":"829","DOI":"10.3390\/molecules25040829","article-title":"Measuring sulforaphane and its metabolites in human plasma: a high throughput method","volume":"25","author":"Langston-Cox","year":"2020","journal-title":"Mol"},{"key":"10.1016\/j.biopha.2023.114490_bib19","doi-asserted-by":"crossref","first-page":"1600766","DOI":"10.1002\/mnfr.201600766","article-title":"Stabilized sulforaphane for clinical use: phytochemical delivery efficiency","volume":"61","author":"Fahey","year":"2017","journal-title":"Mol. Nutr. Food Res."},{"key":"10.1016\/j.biopha.2023.114490_bib20","doi-asserted-by":"crossref","first-page":"7391","DOI":"10.2147\/IJN.S331639","article-title":"Lipid in chips: a brief review of liposomes formation by microfluidics","volume":"16","author":"Zhang","year":"2021","journal-title":"Int. J. Nanomed."},{"key":"10.1016\/j.biopha.2023.114490_bib21","first-page":"47","article-title":"Lipid-based nanoparticles for drug delivery systems","author":"Samimi","year":"2019","journal-title":"Charact. Biol. Nanomater. Drug Deliv. Nanosci. Nanotechnol. Drug Deliv."},{"key":"10.1016\/j.biopha.2023.114490_bib22","article-title":"Effects of size and targeting ligand on biodistribution of liposome nanoparticles in tumor mice","volume":"54","author":"Feng","year":"2013","journal-title":"J. Nucl. Med."},{"key":"10.1016\/j.biopha.2023.114490_bib23","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.3109\/03639045.2014.954582","article-title":"Investigation of factors affecting in vitro doxorubicin release from PEGylated liposomal doxorubicin for the development of in vitro release testing conditions","volume":"41","author":"Shibata","year":"2015","journal-title":"Drug Dev. Ind. Pharm."},{"key":"10.1016\/j.biopha.2023.114490_bib24","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2021.120711","article-title":"Microfluidic-assisted fabrication of phosphatidylcholine-based liposomes for controlled drug delivery of chemotherapeutics","volume":"604","author":"Gkionis","year":"2021","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.biopha.2023.114490_bib25","doi-asserted-by":"crossref","first-page":"3261","DOI":"10.1007\/s11095-015-1702-6","article-title":"A study of liposomal formulations to improve the delivery of aquated cisplatin to a multidrug resistant tumor","volume":"32","author":"Zhao","year":"2015","journal-title":"Pharm. Res."},{"key":"10.1016\/j.biopha.2023.114490_bib26","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fonc.2020.01195","article-title":"Multi-omics characterization of the 4t1 murine mammary gland tumor model","volume":"10","author":"Schr\u00f6rs","year":"2020","journal-title":"Front. Oncol."},{"key":"10.1016\/j.biopha.2023.114490_bib27","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1007\/s11095-013-1171-8","article-title":"Microfluidic preparation of liposomes to determine particle size influence on cellular uptake mechanisms","volume":"31","author":"Andar","year":"2014","journal-title":"Pharm. Res."},{"key":"10.1016\/j.biopha.2023.114490_bib28","doi-asserted-by":"crossref","DOI":"10.1088\/0957-4484\/18\/38\/385101","article-title":"Decreased circulation time offsets increased efficacy of PEGylated nanocarriers targetingfolate receptors of glioma","volume":"18","author":"McNeeley","year":"2007","journal-title":"Nanotechnology"},{"key":"10.1016\/j.biopha.2023.114490_bib29","doi-asserted-by":"crossref","DOI":"10.1016\/j.crphar.2022.100110","article-title":"Evaluation of synergism in drug combinations and reference models for future orientations in oncology","volume":"3","author":"Duarte","year":"2022","journal-title":"Curr. Res. Pharmacol. Drug Discov."},{"key":"10.1016\/j.biopha.2023.114490_bib30","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.lfs.2018.10.034","article-title":"Sulforaphane induces autophagy by inhibition of HDAC6-mediated PTEN activation in triple negative breast cancer cells","volume":"213","author":"Yang","year":"2018","journal-title":"Life Sci."},{"key":"10.1016\/j.biopha.2023.114490_bib31","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.canlet.2020.08.041","article-title":"Co-administration of sulforaphane and doxorubicin attenuates breast cancer growth by preventing the accumulation of myeloid-derived suppressor cells","volume":"493","author":"Rong","year":"2020","journal-title":"Cancer Lett."},{"key":"10.1016\/j.biopha.2023.114490_bib32","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1093\/carcin\/bgg192","article-title":"Sulforaphane: a naturally occurring mammary carcinoma mitotic inhibitor, which disrupts tubulin polymerization","volume":"25","author":"Jackson","year":"2004","journal-title":"Carcinogenesis"},{"key":"10.1016\/j.biopha.2023.114490_bib33","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1007\/s00418-020-01857-x","article-title":"Detection of doxorubicin, cisplatin and therapeutic antibodies in formalin-fixed paraffin-embedded human cancer cells","volume":"153","author":"B\u00f6ckelmann","year":"2020","journal-title":"Histochem. Cell Biol."},{"key":"10.1016\/j.biopha.2023.114490_bib34","doi-asserted-by":"crossref","DOI":"10.1016\/j.smim.2021.101538","article-title":"Versatile neutrophil functions in cancer","volume":"57","author":"Siwicki","year":"2021","journal-title":"Semin. Immunol."},{"key":"10.1016\/j.biopha.2023.114490_bib35","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1084\/jem.181.1.435","article-title":"Inhibition of tumor growth by elimination of granulocytes","volume":"181","author":"Pekarek","year":"1995","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.biopha.2023.114490_bib36","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.yexcr.2009.09.003","article-title":"Neutrophil granulocytes promote the migratory activity of MDA-MB-468 human breast carcinoma cells via ICAM-1","volume":"316","author":"Strell","year":"2010","journal-title":"Exp. Cell Res."},{"key":"10.1016\/j.biopha.2023.114490_bib37","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1111\/j.1365-2613.2007.00539.x","article-title":"The mouse mammary carcinoma 4T1: characterization of the cellular landscape of primary tumours and metastatic tumour foci","volume":"88","author":"DuPr\u00e9","year":"2007","journal-title":"Int. J. Exp. Pathol."},{"key":"10.1016\/j.biopha.2023.114490_bib38","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2020.117599","article-title":"New molecular and biochemical insights of doxorubicin-induced hepatotoxicity","volume":"250","author":"Prasanna","year":"2020","journal-title":"Life Sci."},{"key":"10.1016\/j.biopha.2023.114490_bib39","doi-asserted-by":"crossref","DOI":"10.1016\/j.jpba.2020.113231","article-title":"Total, renal and hepatic clearances of doxorubicin and formation clearance of doxorubicinol in patients with breast cancer: estimation of doxorubicin hepatic extraction ratio","volume":"185","author":"Pippa","year":"2020","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.biopha.2023.114490_bib40","article-title":"The protection afforded by Berberine against chemotherapy-mediated nephropathy in rats involves regulation of the antioxidant axis","author":"Alagal","year":"2022","journal-title":"Basic Clin. Pharmacol. Toxicol."}],"container-title":["Biomedicine &amp; Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332223002780?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332223002780?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T16:18:05Z","timestamp":1781281085000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0753332223002780"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5]]},"references-count":40,"alternative-id":["S0753332223002780"],"URL":"https:\/\/doi.org\/10.1016\/j.biopha.2023.114490","relation":{},"ISSN":["0753-3322"],"issn-type":[{"value":"0753-3322","type":"print"}],"subject":[],"published":{"date-parts":[[2023,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Anticancer effect and safety of doxorubicin and nutraceutical sulforaphane liposomal formulation in triple-negative breast cancer (TNBC) animal model","name":"articletitle","label":"Article Title"},{"value":"Biomedicine & Pharmacotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biopha.2023.114490","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"114490"}}